secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0000950170-24-073046
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta shareholders approve doubling authorized shares; elects Dr. Vratsanos to board
--------------------------------------------------------------------------------

- Shareholders approved increasing authorized common shares from 100M to 200M.
- Elected three Class I directors: Paul Hastings, Angela Thedinga, and new member George Vratsanos.
- Ratified Ernst & Young as independent auditor for fiscal 2024.
- Press release highlights Dr. Vratsanos' R&D leadership at Jnana, Janssen, Novartis, Roche, BMS.
- Nkarta focuses on NK cell therapy for lupus nephritis with NKX019 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024073046/0000950170-24-073046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024073046/nktx-20240613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-073046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer